Planview Completes Acquisition of Tasktop
Planview, a global leader in Portfolio Management and Work Management solutions, today announced it has completed its acquisition of Tasktop, initially announced on May 18.
“Bringing Mik Kersten and the Tasktop team into Planview will help deliver new levels of excellence to companies and industries navigating through change,” said Razat Gaurav, CEO of Planview. “By merging Tasktop’s institutional expertise in scaling software with Planview’s focus on delivering enterprise-scale visibility, we’ve created a new industry powerhouse poised to help organizations connect the business of software delivery and conduct their business transformations with unprecedented confidence and efficiency.”
The combination of Planview and Tasktop means customers work with a single, comprehensive organization with cutting-edge expertise in capabilities ranging from Value Stream Management (VSM) to Strategic Portfolio Management and Enterprise Agile Planning, among others. At a time when organizations are navigating business transformations amid a turbulent macroeconomic landscape, having a single partner that provides intelligence and visibility into the progress of those transformations helps ensure success.
According to a May 2022 Forrester blog, The Market For VSM And SPM Takes A Big Step Forward, “We see the Planview + Tasktop combination having the potential to shake up the (Strategic Portfolio Management) SPM and VSM marketplace and force it to evolve at an even faster pace by putting pressure on existing leaders in agile planning and DevOps management solutions.”
“To succeed with digital transformation, organizations must expand beyond Agile teams to portfolio-level business agility,” said Dean Leffingwell, creator of SAFe® and cofounder, Scaled Agile, Inc. “We’re headed in the right direction. With so many enterprises now deploying SAFe, and the shift from project to product described in Mik Kersten’s book gaining mind share, this new way of working and thinking is finding its way into the CEO’s office. This new paradigm is helping leaders effectively connect the strategic portfolio level with software delivery, which introduces huge opportunities for the business. It is great to see our Scaled Agile partners Planview and Tasktop coming together to help enterprises maximize and accelerate those opportunities.”
The newly combined entity affirms Planview’s leading position globally with 4,500 enterprise customers worldwide, more than 1,300 employees, and a combined FY21 revenue of approximately $400 million. Planview will continue to invest in and support the Tasktop product lines as standalone solutions in the immediate term and will evaluate product direction long term based on customer and industry feedback. As part of the transaction, Tasktop cofounder and CEO, Mik Kersten, has joined Planview as Chief Technology Officer. You can read more about the Tasktop team’s go-forward focus in Mik’s blog.
Sumeru Equity Partners, Tasktop’s lead investor, along with minority investors Elsewhere Partners and Yaletown Partners, and Tasktop’s management will be rolling part of their equity in the new combined entity and will maintain minority interest in Planview alongside its majority shareholders, TPG and TA Associates. Golub Capital provided committed debt financing and Jefferies LLC acted as financial advisors to Planview. Ropes & Gray served as legal counsel to Planview. AGC Partners acted as financial advisors to Tasktop / Sumeru Equity Partners, and Kirkland & Ellis served as legal counsel.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions create an organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005348/en/
Contact information
Leslie Marcotte
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 01:13:00 EET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom